917565-59-4

Upstream product

• 917565-57-2 4-[(2S,3R)-3-[(3S)-3-(acetyloxy)-3-(4-fluorophenyl)propyl]-1-(4-{3-[(methylsulfonyl)amino]prop-1-yn-1-yl}phenyl)-4-oxoazetidin-2-yl]phenyl acetate 
• 145100-50-1 1,1,1-trifluoro-N-(pyridin-2-yl)-N-((trifluoromethyl)sulfonyl)methane sulfonamide 
• 190448-59-0 (1S)-1-(4-fluorophenyl)-3-[(2S,3R)-2-(4-hydroxyphenyl)-1-(4-iodophenyl)-4-oxoazetidin-3-yl]propyl acetate 
• 917565-48-1 4-[(2S,3R)-3-[(3S)-3-(acetyloxy)-3-(4-fluorophenyl)propyl]-1-(4-iodophenyl)-4-oxoazetidin-2-yl]phenyl acetate 
• 917565-58-3 4-[(2S,3R)-3-[(3S)-3-(acetyloxy)-3-(4-fluorophenyl)propyl]-1-(4-{3-[(methylsulfonyl)amino]propyl}phenyl)-4-oxoazetidin-2-yl]phenyl acetate 
• 1039433-06-1 C₃₀H₃₃FN₂O₆S 

Downstream Products

• 1039433-10-7 (1S)-1-(4-fluorophenyl)-3-[(2S,3R)-2-{4-[1-(hydroxymethyl)vinyl]phenyl}-1-(4-{3-[(methylsulfonyl)amino]propyl}phenyl)-4-oxoazetidin-3-yl]propyl acetate 
• 1227267-88-0 dibenzyl (3-{4-[(2S,3R)-3-[(3S)-3-(acetyloxy)-3-(4-fluorophenyl)propyl]-1-(4-{3-[(methylsulfonyl)amino]propyl}phenyl)-4-oxoazetindin-2-yl]phenyl}prop-2-yn-1-yl)malonate 
• 932724-71-5 (1S)-3-[(2S,3R)-2-(4-{2-[5-(acetyloxy)-2.2-dimethyl-1,3-dioxan-5-yl]ethyl}phenyl)-1-(4-{3-[(methylsulfonyl)amino]propyl}phenyl)-4-oxoazetidin-3-yl]-1-(4-fluorophenyl)propyl acetate 
• 1039433-08-3 3-{4-[(2S,3R)-3-[(3S)-3-(acetyloxy)-3-(4-fluorophenyl)propyl]-1-(4-{3-[(methylsulfonyl)amino]propyl}phenyl)-4-oxoazetidin-2-yl]phenyl}-1,1-bis(hydroxymethyl)propyl acetate 
• 932724-70-4 (1S)-3-[(2S,3R)-2-(4-{[5-(acetyloxy)-2,2-dimethyl-1,3-dioxan-5-yl]ethynyl}phenyl)-1-(4-{3-[(methylsulfonyl)amino]propyl}phenyl)-4-oxoazetidin-3-yl]-1-(4-fluorophenyl)propyl acetate 

Relevant academic research and scientific papers

ANTI-HYPERCHOLESTEROLEMIC COMPOUNDS

One object of the instant invention is to provide novel cholesterol absorption inhibitors of Formula I or pharmaceutically acceptable salts thereof.

ANTI-HYPERCHOLESTEROLEMIC COMPOUND

This invention provides a novel crystalline form of N-[3-(4-{(2S,3R)-2-{4-[3,4-dihydroxy-3-(hydroxymethyl)butyl]phenyl}-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxoazetidin-1-yl}phen yl)propyl]methanesulfonamide. The compound is useful for lowering p

Anti-hypercholesterolemic compounds

This invention provides cholesterol absorption inhibitors of Formula I: and the pharmaceutically acceptable salts and esters thereof. The compounds are useful for lowering plasma cholesterol levels, particularly LDL cholesterol, and for treating and preventing atherosclerosis and atherosclerotic disease events.